| Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma (NCT04091126) | GlaxoSmithKline | 2019-12-18 |
| A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors (NCT04214093) | AstraZeneca | 2019-12-16 |
| Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy (NCT04014764) | Notable Labs | 2019-12-15 |
| Lenalidomide Adherence in Older Adults (NCT03779555) | Washington University School of Medicine | 2019-12-13 |
| A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (NCT04177823) | GlaxoSmithKline | 2019-12-09 |
| Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma. (NCT05163405) | Karin B. Ø. Dieperink | 2019-12-01 |
| Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma (NCT04272151) | Chongqing Precision Biotech Co., Ltd | 2019-12-01 |
| Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM (NCT07217119) | GlaxoSmithKline | 2019-11-26 |
| Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma (NCT04151667) | H. Lee Moffitt Cancer Center and Research Institute | 2019-11-22 |
| A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma (NCT04174196) | Memorial Sloan Kettering Cancer Center | 2019-11-19 |
| Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study. (NCT04260490) | Centre Hospitalier Universitaire de la Guadeloupe | 2019-11-19 |
| A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (NCT04133636) | Janssen Research & Development, LLC | 2019-11-07 |
| A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat (NCT04150289) | pharmaand GmbH | 2019-11-04 |
| Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial (NCT04099901) | Radboud University Medical Center | 2019-11-04 |
| IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic (NCT03683277) | Intergroupe Francophone du Myelome | 2019-11-03 |
| 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT) (NCT03003728) | University of Arkansas | 2019-11-01 |
| Efficacy and Safety Evaluation of BCMA-UCART (NCT03752541) | Bioray Laboratories | 2019-11-01 |
| Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease (NCT04166565) | Stichting European Myeloma Network | 2019-10-31 |
| Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients (NCT04108624) | University of Chicago | 2019-10-30 |
| Bone Healing During Ninlaro Exposure (NCT04028115) | Thomas Lund | 2019-10-24 |
| A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma (NCT04295018) | Peking Union Medical College Hospital | 2019-10-23 |
| Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple Myeloma (NCT04122092) | Shanghai Changzheng Hospital | 2019-10-20 |
| Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy (NCT03993912) | University Hospital, Lille | 2019-10-17 |
| A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma (NCT04182581) | Xijing Hospital | 2019-10-15 |
| A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors (NCT03997968) | Cyteir Therapeutics, Inc. | 2019-10-09 |
| Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (NCT03909412) | Hackensack Meridian Health | 2019-10-08 |
| Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (NCT04126200) | GlaxoSmithKline | 2019-10-07 |
| NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma (NCT04136756) | Nektar Therapeutics | 2019-10-07 |
| Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma (NCT03695744) | Singapore General Hospital | 2019-10-02 |
| Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological Disease (NCT04039100) | Rigshospitalet, Denmark | 2019-10-01 |
| A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) (NCT03989414) | Celgene | 2019-09-30 |
| A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation (NCT03608501) | Takeda | 2019-09-30 |
| Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients (NCT03792763) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2019-09-30 |
| First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone (NCT04075721) | EMD Serono Research & Development Institute, Inc. | 2019-09-26 |
| Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) (NCT03915184) | CARsgen Therapeutics Co., Ltd. | 2019-09-25 |
| Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients (NCT04217967) | Peking Union Medical College Hospital | 2019-09-24 |
| Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission (NCT03376477) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2019-09-23 |
| Ixazomib + Pomalidomide + Dexamethasone In MM (NCT04094961) | Omar Nadeem, MD | 2019-09-18 |
| A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma (NCT04322292) | Institute of Hematology & Blood Diseases Hospital, China | 2019-09-12 |
| Treatment of Hematological Malignancy With Novel CAR-T Cells. (NCT04191941) | Timmune Biotech Inc. | 2019-09-01 |
| Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma (NCT04097301) | AGC Biologics S.p.A. | 2019-08-27 |
| A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma (NCT04036461) | Celgene | 2019-08-26 |
| S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (NCT04071457) | SWOG Cancer Research Network | 2019-08-13 |
| Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression (NCT04137523) | University of Turin, Italy | 2019-08-12 |
| Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies (NCT04068597) | CellCentric Ltd. | 2019-08-09 |
| Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) (NCT04045795) | Sanofi | 2019-08-06 |
| A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment (NCT04035226) | Janssen-Cilag Ltd. | 2019-08-02 |
| Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma (NCT03994705) | Cartesian Therapeutics | 2019-08-01 |
| B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma (NCT03931421) | First Affiliated Hospital of Zhejiang University | 2019-07-31 |
| An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients (NCT03606577) | Nantes University Hospital | 2019-07-30 |
| A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (NCT03984097) | Takeda | 2019-07-29 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT04045028) | Genentech, Inc. | 2019-07-22 |
| Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients (NCT04025450) | The First Affiliated Hospital of Soochow University | 2019-07-15 |
| BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma (NCT03943472) | Hrain Biotechnology Co., Ltd. | 2019-07-08 |
| Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma (NCT04162119) | Chinese PLA General Hospital | 2019-07-07 |
| Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial (NCT04024384) | Assistance Publique - Hôpitaux de Paris | 2019-07-01 |
| Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma (NCT04003168) | Hrain Biotechnology Co., Ltd. | 2019-07-01 |
| A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant (NCT04096066) | Fondazione EMN Italy Onlus | 2019-07-01 |
| A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma (NCT03933735) | AbbVie | 2019-06-24 |
| A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) (NCT03815279) | Landspitali University Hospital | 2019-06-24 |
| Transcriptomics and Epigenetics Analysis in Drug-Resistance of Multiple Myeloma (NCT05888636) | Regina Elena Cancer Institute | 2019-06-18 |
| Role of the Host Microbiota and Il-17 in Favoring Multiple Myeloma Progression (NCT05712967) | IRCCS San Raffaele | 2019-06-14 |
| Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1) (NCT03975907) | CARsgen Therapeutics Co., Ltd. | 2019-06-10 |
| Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma (NCT03436342) | Peking Union Medical College Hospital | 2019-06-01 |
| Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab (NCT03871829) | Janssen Research & Development, LLC | 2019-05-31 |
| Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma (NCT03657420) | Massachusetts General Hospital | 2019-05-30 |
| A Registry Study of Participants With Multiple Myeloma in Latin America (NCT03955900) | Janssen-Cilag Ltd. | 2019-05-29 |
| Sleep Apnea in Patients With MGUS and MM (NCT04114084) | Michael Tomasson | 2019-05-23 |
| Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM) (NCT03795597) | Loyola University | 2019-05-22 |
| Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics (NCT04678089) | Beijing Chao Yang Hospital | 2019-05-16 |
| Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) (NCT03729804) | University of Chicago | 2019-05-07 |
| Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM (NCT03940833) | Asclepius Technology Company Group (Suzhou) Co., Ltd. | 2019-05-01 |
| A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy (NCT03785184) | AbbVie | 2019-04-29 |
| A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (NCT03901963) | Janssen Research & Development, LLC | 2019-04-26 |
| Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara (NCT03896737) | European Myeloma Network B.V. | 2019-04-16 |
| Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (NCT03651128) | Celgene | 2019-04-16 |
| Immune Profiling in Multiple Myeloma (NCT04135079) | Mario Boccadoro | 2019-04-15 |
| Carfilzomib in Combination for the Treatment of RR MM (NCT04004338) | Black Sea Hematology Association | 2019-04-14 |
| A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (NCT03650491) | Fortis Therapeutics, Inc. | 2019-04-03 |
| BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease (NCT04271644) | Chongqing Precision Biotech Co., Ltd | 2019-04-01 |
| RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma (NCT03908138) | Shandong Provincial Hospital | 2019-03-30 |
| Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) (NCT03848845) | GlaxoSmithKline | 2019-03-14 |
| An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments (NCT03828292) | GlaxoSmithKline | 2019-03-14 |
| Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone (NCT03809780) | Kosin University Gospel Hospital | 2019-03-11 |
| Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma (NCT04186052) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2019-03-08 |
| A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM) (NCT03875495) | Genenta Science | 2019-03-06 |
| High Dose Ascorbic Acid for Plasma Cell Disorders (NCT03602235) | Christopher Strouse | 2019-03-05 |
| Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma (NCT03711864) | Peking Union Medical College Hospital | 2019-02-25 |
| Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma (NCT03782064) | Beth Israel Deaconess Medical Center | 2019-02-22 |
| Post-Op Pain Control for Prophylactic Intramedullary Nailing. (NCT03823534) | St. Louis University | 2019-02-20 |
| Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma (NCT03500445) | University of Chicago | 2019-02-13 |
| sdAb-based TRNT of Multiple Myeloma: a Feasibility Study (NCT03956615) | Universitair Ziekenhuis Brussel | 2019-02-12 |
| MYeloma Resistance And Clonal Evolution (NCT03807128) | Nantes University Hospital | 2019-02-11 |
| Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma (NCT03757221) | University Hospital, Caen | 2019-02-07 |
| Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning (NCT03852407) | University of Liege | 2019-02-04 |
| Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT) (NCT03748953) | Millennium Pharmaceuticals, Inc. | 2019-01-24 |
| A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma (NCT03758417) | Nanjing Legend Biotech Co. | 2019-01-23 |
| Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma (NCT03761108) | Regeneron Pharmaceuticals | 2019-01-23 |
| Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders. (NCT03344328) | University Hospital, Clermont-Ferrand | 2019-01-15 |
| A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma (NCT03710915) | HitGen Inc. | 2019-01-12 |